Ultragenyx Pharmaceutical Inc. financial data

Symbol
RARE on Nasdaq
Industry
Pharmaceutical Preparations
Location
60 Leveroni Court, Novato, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 275 % -22.4%
Quick Ratio 13.5 % +23.8%
Debt-to-equity 543 % +35.5%
Return On Equity -266 % -8.04%
Return On Assets -41.4 % +15.9%
Operating Margin -114 % +31.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 92.2M shares +28.9%
Common Stock, Shares, Outstanding 92.1M shares +28.9%
Common Stock, Value, Issued 92K USD +29.6%
Weighted Average Number of Shares Outstanding, Basic 86.6M shares +22.1%
Weighted Average Number of Shares Outstanding, Diluted 86.6M shares +22.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 481M USD +19.5%
Research and Development Expense 658M USD -11%
Operating Income (Loss) -549M USD +18.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -587M USD +17.9%
Income Tax Expense (Benefit) -1.74M USD -129%
Net Income (Loss) Attributable to Parent -585M USD +18.8%
Earnings Per Share, Basic -7.22 USD/shares +29.6%
Earnings Per Share, Diluted -7.22 USD/shares +29.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 481M USD +371%
Accounts Receivable, after Allowance for Credit Loss, Current 106M USD +50.3%
Inventory, Net 40.1M USD +42%
Other Assets, Current 54.7M USD
Assets, Current 965M USD +37.4%
Property, Plant and Equipment, Net 279M USD -3.56%
Operating Lease, Right-of-Use Asset 23.9M USD -8.08%
Intangible Assets, Net (Excluding Goodwill) 166M USD +5.06%
Goodwill 44.4M USD 0%
Other Assets, Noncurrent 53.8M USD +103%
Assets 1.62B USD +23.4%
Accounts Payable, Current 59.8M USD +42%
Employee-related Liabilities, Current 61.1M USD -0.48%
Accrued Liabilities, Current 154M USD -7.89%
Liabilities, Current 273M USD +11.7%
Deferred Income Tax Liabilities, Net 30.1M USD -5.08%
Operating Lease, Liability, Noncurrent 30.6M USD +54.3%
Other Liabilities, Noncurrent 15.2M USD +46.2%
Liabilities 1.19B USD +0.32%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.1M USD +64.7%
Retained Earnings (Accumulated Deficit) -3.69B USD -18.8%
Stockholders' Equity Attributable to Parent 432M USD +235%
Liabilities and Equity 1.62B USD +23.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -191M USD -21.6%
Net Cash Provided by (Used in) Investing Activities 94.4M USD -15.2%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -97M USD -111%
Deferred Tax Assets, Valuation Allowance 1.04B USD +15.8%
Deferred Tax Assets, Gross 1.04B USD +15.7%
Operating Lease, Liability 43.2M USD +37.4%
Payments to Acquire Property, Plant, and Equipment 3.21M USD -87.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -583M USD +18.4%
Lessee, Operating Lease, Liability, to be Paid 54.4M USD +55.6%
Property, Plant and Equipment, Gross 374M USD +15.7%
Operating Lease, Liability, Current 12.6M USD +8.62%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.9M USD +4.92%
Lessee, Operating Lease, Liability, to be Paid, Year One 16.2M USD +22.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +44.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.2M USD +218%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.43M USD +29.1%
Deferred Tax Assets, Operating Loss Carryforwards 266M USD +14.8%
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 80M USD +19.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.87M USD +97.9%
Additional Paid in Capital 4.12B USD +27.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 8.85M USD +68.9%
Deferred Tax Assets, Net of Valuation Allowance 5.96M USD -3%
Share-based Payment Arrangement, Expense 145M USD +10%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares